jaktinib hydrochloride cream / Suzhou Zelgen - LARVOL DELTA

Jaktinib Hydrochloride Cream For Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=107 | Completed | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (clinicaltrials.gov) - P1/2 | N=160 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting ➔ Active, not recruiting | N=120 ➔ 160 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Jaktinib Hydrochloride Cream For Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=107 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Jaktinib Hydrochloride Cream For Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=92 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Emerging drugs for the treatment of alopecia areata. (PubMed, Expert Opin Emerg Drugs) - "Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication...AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of co-morbidities."

Journal • Alopecia

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Alopecia

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial completion date: Jun 2021 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Alopecia

Jaktinib Hydrochloride Cream For Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=92; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Jaktinib Hydrochloride Cream For Atopic Dermatitis (clinicaltrials.gov) - P1/2; N=92; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial completion date: Dec 2023 ➔ Dec 2022; Initiation date: Aug 2020 ➔ Dec 2020; Trial primary completion date: Aug 2023 ➔ Dec 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (clinicaltrials.gov) - P1/2; N=120; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alopecia • Dermatopathology